Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (?d) T Cell Engager Therapies Targeting Solid Tumors
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire Adaptate Biotherapeutics (“Adaptate”), a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vd1) gamma delta (?d) T cells.
Source: businesswireindia.com